Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Maximilian Rost et al. published in JTO Clinical and Research Reports:
“Report from JTO Clinical and Research Reports on 3L treatment patterns in SCLC from the German CRISP Registry (AIO-TRK-0315). Note that most do not receive 3L. In this cohort, 1L therapy typically carbo, etop, atezolizumab, and 2L was topotecan / CAV. 3L options were paclitaxel (22%) and topotecan (22%).
Clear unmet need in 3L for SCLC, as overall outcomes remain quite poor. Median rwPFS 2.2m and median OS was 4.4m – hoping introduction of novel agents (tarlatamab, lurbinectedin, ADCs) leads to improvements.”
Title: Treatment patterns, outcome, and QoL of ES-SCLC patients receiving third-line therapy – Data from the German CRISP Registry (AIO-TRK-0315): A Brief Report
Authors: Maximilian Rost, Rieke Fischer, Martin Reck, Thomas Gauler, Cornelius Waller, Petros Christopoulos, Petra Hoffknecht, Martina Jänicke, Annette Fleitz, Andrea Härtschel, Carolin Lennartz, Paula Ludwig, Annika Groth, Michael Bendel, Jan Stratmann, Frank Griesinger, Michael Thomas, Wilfried E.E. Eberhardt, Martin Sebastian
You can read the Full Article in JTO Clinical and Research Reports.
More posts featuring Stephen V Liu.
